ArticleScientific reports2025
A retrospective analysis on maternal and neonatal outcomes in pSS/AITD pregnancies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- IUGR remodels glycogen synthesis in CG-IUGR rats.Endocrine connections · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The combined impact of concurrent primary Sjögren's syndrome (pSS) and autoimmune thyroid disease (AITD) on pregnancy outcomes remains underreported. A retrospective analysis was conducted on 115 pregnant patients diagnosed with pSS and delivering at the Third Affiliated Hospital of Guangzhou Medical University from January 2009 to July 2023. The effects of AITD on maternal and neonatal outcomes were examined and compared to a control group without AITD. In the group with pSS and AITD, the pregnancy loss rate was significantly higher than in the non-AITD group (P = 0.015), primarily reflected in the increased rate of neonatal death (P = 0.029). The proportion of term births and vaginal deliveries in the AITD group was notably reduced compared to the non-AITD group (54% vs. 81.5%; 16.0% vs. 41.5%; P = 0.001 and P = 0.003, respectively). No significant differences were observed in other maternal pregnancy outcomes, including induced abortion, spontaneous abortion, therapeutic abortion, and premature delivery (P > 0.05). The average birth weight of newborns in the pSS with AITD group was significantly lower than in the pSS without AITD group (2587.70 ± 720.50 g vs. 2812.54 ± 495.30 g, P < 0.001). Additionally, the rate of low-birth-weight infants in the pSS with AITD group was higher than in the pSS without AITD group (39.0% vs. 19.7%, P = 0.032). However, no significant differences were found between the two groups in the rates of fetal death, neonatal live birth, and fetal distress (P > 0.05). These results emphasize the importance of monitoring and managing thyroid health during pregnancy to optimize maternal and neonatal outcomes. Further exploration is essential to unravel the precise mechanisms through which AITD impacts fetal growth and to identify potential interventions to mitigate these effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.